InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.049

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Innovative collaboration further expands Sofra platform 27 Apr 2026 8:21AM $0.076 $0.049 fallen by 35.53%
$15 March 2026 Quarterly Activities Report and Appendix 4C 24 Apr 2026 9:23AM $0.069 $0.049 fallen by 28.99%
$15 Positive SOF-SKN dosing data shows prolonged skin retention 22 Apr 2026 8:35AM $0.066 $0.049 fallen by 25.76%
$15 Noxopharm appoints Dr Olivier Laczka as new CEO 15 Apr 2026 9:27AM $0.058 $0.049 fallen by 15.52%
$15 Change of & Final Directors Interest Notice (App 3Y & 3Z)-GM 15 Apr 2026 9:22AM $0.058 $0.049 fallen by 15.52%
$15 Resignation of Chief Executive Officer 14 Apr 2026 9:55AM $0.058 $0.049 fallen by 15.52%
$15 Appendix 4D and FY2026 Half Year Financial Report 27 Feb 2026 1:40PM $0.067 $0.049 fallen by 26.87%
$15 Notice under Section 708A(5)(e) of the Corps Act 27 Feb 2026 9:48AM $0.065 $0.049 fallen by 24.62%
$15 Application for quotation of securities - NOX 27 Feb 2026 9:47AM $0.065 $0.049 fallen by 24.62%
$15 R&D rebate strengthens cash position 27 Feb 2026 9:35AM $0.065 $0.049 fallen by 24.62%
$15 At-the-Market (ATM) agreement with Acuity Capital 27 Feb 2026 9:06AM $0.065 $0.049 fallen by 24.62%
$15 Sofra breakthrough science publish in major medical journal 11 Feb 2026 8:17AM $0.070 $0.049 fallen by 30%
$15 December 2025 Quarterly Activities Report and Appendix 4C 30 Jan 2026 9:09AM $0.077 $0.049 fallen by 36.36%
$15 HERACLES clinical trial successfully completed 21 Jan 2026 9:00AM $0.078 $0.049 fallen by 37.18%
$15 Notice under s708A(12C)(e) of the Corporations Act 2001 2 Jan 2026 9:16AM $0.093 $0.049 fallen by 47.31%
$15 Notification regarding unquoted securities - NOX 2 Jan 2026 9:07AM $0.093 $0.049 fallen by 47.31%
$15 Notification of cessation of securities - NOX 2 Jan 2026 9:02AM $0.093 $0.049 fallen by 47.31%
$15 Change of Director's Interest Notice - FB 12 Dec 2025 9:48AM $0.099 $0.049 fallen by 50.51%
$15 Notice under s708A(12C)(e) of the Corporations Act 2001 12 Dec 2025 9:43AM $0.099 $0.049 fallen by 50.51%
$15 Notification regarding unquoted securities - NOX 12 Dec 2025 9:35AM $0.099 $0.049 fallen by 50.51%
$15 HERACLES clinical trial Update 5 3 Dec 2025 8:21AM $0.097 $0.049 fallen by 49.48%
$15 Results of Meeting 18 Nov 2025 4:48PM $0.089 $0.049 fallen by 44.94%
$15 Noxopharm 2025 AGM Corporate Presentation 18 Nov 2025 9:17AM $0.099 $0.049 fallen by 50.51%
$15 Noxopharm 2025 AGM Chair Address 18 Nov 2025 9:06AM $0.099 $0.049 fallen by 50.51%
$15 First dose in HERACLES clinical trial Part Two 17 Nov 2025 8:27AM $0.090 $0.049 fallen by 45.56%

26 - 50 of 806 results

Page 2 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.